What are the side effects of margituximab on the lungs?

Margetuximab (margetuximab-cmkb), as a targeted monoclonal antibody against HER2-positive tumors, is widely used clinically to treat HER2-expressing breast cancer patients. Although its therapeutic effect has been confirmed, like most immune-related drugs, the use of margetuximab may also be associated with certain pulmonary side effects, especially immune-mediated pulmonary inflammatory reactions.

Pulmonary side effects are mainly manifested as interstitial lung disease (ILD, Interstitial Lung Disease) and immune-related pneumonia. Both diseases involve inflammation and fibrosis of lung tissue, which may lead to impaired respiratory function. When patients experience pulmonary side effects, they often present with symptoms such as cough, shortness of breath, fever or fatigue. These clinical manifestations are similar to other lung diseases, so special vigilance is required during diagnosis.

According to overseas clinical trials and post-marketing surveillance data, although the incidence of pulmonary side effects caused by margetuximab is relatively low, once symptoms occur, the drug needs to be discontinued in time and targeted treatment is required to prevent the condition from worsening. Experts recommend that during treatment, especially patients with a history of lung disease or chest radiation therapy, regular lung function tests and imaging evaluations should be performed to detect lung abnormalities early.

The drug instructions also emphasize that patients and doctors need to pay close attention to changes in respiratory symptoms, and if persistent coughing or difficulty breathing occurs, detailed examinations should be conducted as soon as possible. The mechanism of immune-related pulmonary side effects is mainly related to the drug activating the body's immune system and inducing the release of inflammatory mediators. Although this immune activation is helpful in anti-tumor, it may also cause damage to normal lung tissue.

Therefore, clinicians should weigh the pros and cons when using medication and adjust the treatment plan according to the patient's condition. It is worth noting that there are currently no specific preventive measures for pulmonary side effects of margetuximab, but through standardized management and timely intervention, the vast majority of patients can effectively control pulmonary adverse reactions and ensure treatment safety.

Reference materials:https://www.margenza.com/